A006280 Stock Overview
A biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
GC Biopharma Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩173,800.00 |
52 Week High | ₩177,500.00 |
52 Week Low | ₩93,000.00 |
Beta | 1.03 |
11 Month Change | 10.84% |
3 Month Change | 35.89% |
1 Year Change | 83.72% |
33 Year Change | -35.63% |
5 Year Change | 48.55% |
Change since IPO | -41.60% |
Recent News & Updates
Is GC Biopharma (KRX:006280) A Risky Investment?
Oct 17There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues
Aug 02Recent updates
Is GC Biopharma (KRX:006280) A Risky Investment?
Oct 17There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues
Aug 02A Look At The Fair Value Of GC Biopharma Corp. (KRX:006280)
Jul 12Is GC Biopharma (KRX:006280) A Risky Investment?
May 25GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry
Mar 08We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt
May 02Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?
Mar 10Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%
Feb 18Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet
Jan 31Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)
Jan 14What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition
Dec 27Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Dec 09Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 21Shareholder Returns
A006280 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 8.9% | 2.0% | 0.1% |
1Y | 83.7% | 57.0% | 6.3% |
Return vs Industry: A006280 exceeded the KR Biotechs industry which returned 57% over the past year.
Return vs Market: A006280 exceeded the KR Market which returned 6.3% over the past year.
Price Volatility
A006280 volatility | |
---|---|
A006280 Average Weekly Movement | 8.5% |
Biotechs Industry Average Movement | 9.1% |
Market Average Movement | 6.8% |
10% most volatile stocks in KR Market | 12.2% |
10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A006280 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A006280's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1967 | 2,016 | Il-Sup Huh | www.globalgreencross.com |
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj.
GC Biopharma Corp. Fundamentals Summary
A006280 fundamental statistics | |
---|---|
Market cap | ₩1.98t |
Earnings (TTM) | -₩38.20b |
Revenue (TTM) | ₩1.62t |
1.2x
P/S Ratio-51.9x
P/E RatioIs A006280 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A006280 income statement (TTM) | |
---|---|
Revenue | ₩1.62t |
Cost of Revenue | ₩1.16t |
Gross Profit | ₩457.90b |
Other Expenses | ₩496.09b |
Earnings | -₩38.20b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.35k |
Gross Margin | 28.29% |
Net Profit Margin | -2.36% |
Debt/Equity Ratio | 52.3% |
How did A006280 perform over the long term?
See historical performance and comparison